Dr Kiran Mazumdar-Shaw, CMD, Biocon
On January 22, 2014, Biocon and US-based Advaxis, declared that they have signed an exclusive licensing agreement for the co-development and commercialization of ADXS-HPV.
ADXS-HPV is a novel cancer immunotherapy for the treatment of human papillomavirus (HPV), associated with cervical cancer in women, for India and key emerging markets.
Advaxis is a clinical-stage biotechnology company in New Jersey (US) involved in developing next generation cancer immunotherapies.
Talking about the pact, Biocon's CMD, Dr Kiran Mazumdar-Shaw said, "Biocon is committed to finding solutions for women's health issues. This partnership will enable us to develop ADXS-HPV, a novel immunotherapy to combat cervical cancer in women. It is a promising technology that has the ability to suppress the tumor inside the micro-environment, and can be leveraged for developing several other novel therapeutics to address various unmet medical needs of patients in India and other emerging markets."
According to World Health Organization (WHO), in 2008 there were over 530,000 new cases of cervical cancer worldwide, and 90% of these were reported in developing countries.